MOUNJARO KWIKPEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MOUNJARO KWIKPEN (MOUNJARO KWIKPEN).
Glucagon-like peptide-1 (GLP-1) receptor agonist; enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, and promotes satiety.
| Metabolism | Catabolized via proteolytic degradation by general proteases; not significantly metabolized by CYP450 enzymes. |
| Excretion | Approximately 70% of the administered dose is eliminated via the kidneys (urine) and 30% via the feces (biliary/fecal route). |
| Half-life | Terminal elimination half-life is approximately 5 days (range 4-6 days), supporting once-weekly dosing. Steady state is achieved after 4 weeks of once-weekly administration. |
| Protein binding | >99% bound to plasma proteins, predominantly to albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.5 L/kg, indicating distribution primarily into extracellular fluid and limited tissue binding. |
| Bioavailability | Subcutaneous: Absolute bioavailability is approximately 80% (range 70-90%). |
| Onset of Action | Subcutaneous injection: Onset of glycemic effect is observed within 1 day after the first dose, with peak clinical effect on fasting and postprandial glucose reduction typically seen at 4-8 weeks. |
| Duration of Action | Duration of action is approximately 7 days following a single subcutaneous dose, allowing for once-weekly dosing. Effects on glucose and weight loss persist for several weeks after discontinuation. |
Subcutaneous injection once weekly. Initial dose: 2.5 mg for 4 weeks; then increase to 5 mg for at least 4 weeks; further increments of 2.5 mg every 4 weeks as tolerated, up to a maximum of 15 mg once weekly.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²). Limited data in severe renal impairment (eGFR <30 mL/min/1.73 m²) or end-stage renal disease; not recommended. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients (<18 years). No approved pediatric dosing. |
| Geriatric use | No specific dose adjustment required based on age alone. Consider renal function and overall health status; monitor for gastrointestinal effects and volume depletion. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MOUNJARO KWIKPEN (MOUNJARO KWIKPEN).
| Breastfeeding | Unknown if tirzepatide is excreted in human milk. No data on M/P ratio. Because of potential for adverse reactions in nursing infants, breast-feeding is not recommended during use and for at least 4 weeks after last dose. |
| Teratogenic Risk | Based on animal studies, tirzepatide may cause fetal harm. GLP-1 receptor agonists have been associated with reduced fetal growth in animal studies. Avoid use in pregnancy, especially during organogenesis (first trimester). Insufficient human data to assess risk in second and third trimesters. Consider discontinuing therapy if pregnancy occurs. |
■ FDA Black Box Warning
Not applicable (no FDA boxed warning).
| Serious Effects |
["Personal or family history of medullary thyroid carcinoma (MTC)","Multiple endocrine neoplasia syndrome type 2 (MEN-2)","Hypersensitivity to tirzepatide or any excipients","Not recommended for use with other GLP-1 receptor agonists or with incretin-based therapies"]
| Precautions | ["Risk of thyroid C-cell tumors (medullary thyroid carcinoma); contraindicated in patients with personal or family history of MTC or MEN-2","Acute pancreatitis; discontinue if suspected","Hypoglycemia risk, especially when used with insulin or sulfonylureas","Diabetic retinopathy complications associated with rapid glycemic improvement","Acute kidney injury risk in patients with renal impairment","Gastrointestinal adverse reactions (nausea, vomiting, diarrhea)","Heart rate increase; monitor if symptomatic","Immunogenicity and risk of antibody formation"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal weight, blood glucose, and metabolic status. Fetal growth should be monitored via ultrasound if conception occurs during therapy. Assess for potential teratogenic effects if exposure occurs in first trimester. No specific fetal monitoring guidelines exist; use standard prenatal care. |
| Fertility Effects | In animal studies, tirzepatide caused an increase in estrous cycle length and decreased fertility at high doses. Human data are lacking. The effect on human fertility is unknown. Women of childbearing potential should use effective contraception. |